首页> 外国专利> MACOZINONE-BASED PHARMACEUTICAL COMPOSITION FOR TREATMENT OF TUBERCULOSIS INCLUDING MULTI- AND EXTENSIVELY DRUG-RESISTANT FORMS THEREOF

MACOZINONE-BASED PHARMACEUTICAL COMPOSITION FOR TREATMENT OF TUBERCULOSIS INCLUDING MULTI- AND EXTENSIVELY DRUG-RESISTANT FORMS THEREOF

机译:基于Macozinone的药物组合物,用于治疗结核病,包括多且广泛的耐药形式

摘要

FIELD: medicine.;SUBSTANCE: group of inventions relates to the field of medicine and pharmaceuticals. The first object constitutes a gastroretentive swellable mucoadhesive tablet for controlled release of macozinone in the stomach and upper small intestine, constituting a combined system including a complex of macozinone or a pharmaceutically acceptable salt thereof in a therapeutically effective amount and cyclodextrin in form of granules coated with a layer of mucoadhesive polymer, wherein said layer includes a solubiliser, and pressed into a polymer matrix based on two hydrophilic soluble or one hydrophilic soluble and one insoluble swellable and mucoadhesive polymers, and an additional pharmaceutically acceptable excipient. The second object constitutes an application of the tablet for prevention and/or treatment of a disease caused by mycobacteria.;EFFECT: technical result of the invention is production of a gastroretentive tablet containing macozinone or a pharmaceutically acceptable salt thereof with modified release of an active substance with an increased relative bioavailability, providing long-term maintenance of a therapeutically significant concentration of an active substance in the body under conditions of a single oral administration, exhibiting high compliance and suitability for use in regimens of complex therapy of tuberculosis infection.;26 cl, 4 dwg, 11 tbl, 14 ex
机译:田地:医学。物质:本发明组涉及药物和药物领域。第一个物体构成胃内溶胀性溶胀的粘膜粘附片,用于胃和上小肠中的Macozinone的控制释放,构成包括在治疗有效量和环糊精中的多胶酮或其药学上可接受的盐的组合系统以涂覆的形式一层粘膜粘附性聚合物,其中所述层包括溶解器,并基于两个亲水性可溶性或一种亲水性可溶性和一种不溶性可溶胀的和粘膜粘附性聚合物压入聚合物基质中,以及另外的药学上可接受的赋形剂。第二个目的构成片剂的应用以预防和/或治疗由分枝杆菌引起的疾病。;效果:本发明的技术结果是制备含有多种子胶质或其药学上可接受的盐的胃动住片剂,其具有激活的修饰释放具有增加的相对生物利用度的物质,在单个口服给药的条件下,在身体的条件下,提供高度依从性和适用于结核治疗的核心感染的方案的病症,在身体中提供治疗上显着的活性物质的长期维持。; 26 CL,4 DWG,11 TBL,14 ex

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号